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Dendritic cells (DCs) are a specialized family of professional
antigen presenting cells that serve as a bridge linking the
innate and adaptive arms of our immune system. DCs
sense pathogens or interact with harmless antigens or non-
pathogenic bacteria thereby tightly regulating the balance
between tolerance and immunity. Despite their indispensable
role in eliciting immune responses, DCs are a rather rare and
heterogeneous type of immune cell, which differ in pheno-
type and function depending on maturation status, subsets,
and age as well as their localization and microenvironment.
Although scarce in numbers, cultured or naturally occurring
DCs have been extensively investigated in clinical trials for
both their capacity of priming antigen specific cytotoxic and
helper T cells and humoral responses and their potential
to induce immunological memory, which are capacities that
distinct them from other, nowadays, exploited forms of
immunotherapy.
Cancer immunotherapy has been designated the scien-
tific breakthrough of the year in 2013. This has a broader
implication for DC research in general, as DC based therapy
can also be used to induce tolerance in autoimmune or
immune-based diseases or to induce or improve immunity
in, for instance, virally infected individuals. In this special
issue we present two original research articles as well as five
review papers on the therapeutic potential of the use of DC
subsets forDCbased immunotherapy in cancer, autoimmune
disorders, and infectious diseases.
In their paper “Linking CD11b+ Dendritic Cells and Nat-
ural Killer TCells to Plaque Inflammation inAtherosclerosis”
M. Rombouts et al. performed extensive immune profiling
in mice to investigate risk factors for plaque inflammation
during atherosclerosis. They demonstrate that circulating
CD11b+ cDC and NKT cells show great potential to reflect
the inflammatory status in the atherosclerotic plaque. This
may provide biomarkers with which atherosclerotic lesion
progression can be monitored and may provide leads for
immune cell based interventions.
J. Klarquist et al. provide an oversight of the changes in
DC composition, maturation, and functionality in patients
with systemic lupus erythematosus (SLE) and mouse models
of spontaneous SLE. Based on the similarities betweenhuman
and murine DC subsets as well as their reported relevance
to disease, they suggest that mouse models provide a useful
platform for the identification, dissection, and targeting of
the DC intrinsic and extrinsic processes that facilitate the
development, progression, and possibly a cure for SLE.
In the paper entitled “Immunity and Tolerance Induced
by Intestinal Mucosal Dendritic Cells”, J. Aliberti describes
the tolerogenic potential of DC in the digestive tract under
steady-state conditions. The various DC subsets orchestrate
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tolerogenic responses towards commensal gut flora and they
orchestrate powerful immune responses directed against
invading pathogens. Failure to successfully complete this task
may result in inflammatory bowel disease, food allergy, or
celiac disease. Insight into the various DC subsets in the gut
and the factors that influence their function may provide
novel druggable targets as a basis for novel therapies.
Immunological tolerance remains a challenge in clinical
organ transplantation and in management of autoimmune
diseases. Tol-DCs are being regarded as a powerful tool to
induce immune homeostasis in autoimmune diseases and as
such are currently explored in clinical trials. In the review
entitled “Metabolism Is Central to Tolerogenic Dendritic Cell
Function”W. J. Sim et al. provide a thorough overview of how
metabolic reprogramming of DCs drives differential cellular
function and how this specifically contributes to pathologies.
Furthermore, they describe and link tolerogenic DCs with
immunosuppressive cytokines, for example, IL-10, and how
these drive the shift in metabolism during TLR stimulation.
Finally, they provide an overview on how pharmacological
manipulation of the DC metabolism can be exploited for the
generation of DC vaccines.
As the field of tolerogenic DC treatments moves forward,
the need has arisen for the development of standardized
protocols for the generation and application of DCs to allow
comparison between different treatments and streamline the
time from bench to bedside. A. T. Brinke et al. outline
the efforts of the European A FACTT (Action to Focus
and Accelerate Cell Based Tolerance Inducing Therapies)
network that aims to harmonize DC production protocols,
functional quality control parameters, immune monitoring
parameters, and therapeutic regulations in order to accelerate
the implementation of cell based tolerance inducing therapies
in the clinic.
Currently, blood DC subsets are explored for the first
time in clinical trials for treating metastatic cancer patients.
S. P. Sittig et al. probed the potential of blood DC subsets
to polarize and stimulate T cells. They specifically compared
human plasmacytoid DCs (pDCs), BDCA1+ myeloid DCs
(mDCs), and BDCA3+ mDCs and their ability to respond
to TLR ligation and prime naive CD4+ T helper cells in an
allogenic antigen unspecific and autologous antigen specific
fashion. Although they clearly observed differences in the
activation profile of the distinct DC subsets, all activated DC
subsets were efficient in eliciting the production of IFN-𝛾 by
naive CD4+ T helper cells. Their findings further establish
all three human blood DCs, despite their differences, as
promising candidates for immunostimulatory effectors in
cancer immunotherapy.
In the review “Pathogen-Associated Molecular Patterns
Induced Crosstalk between Dendritic Cells, T Helper Cells,
and Natural Killer Helper Cells Can Improve Dendritic Cell
Vaccination,” T. Oth et al. describe the optimization of ex
vivo generated DC vaccines by using rationally designed
combinations of interferon gamma and different pathogen-
associated molecular patterns for maturation. In this way, a
cellular interplay is stimulated between key players of the
antitumor response, DC, T helper 1 cells, natural killer cells,
and cytotoxic T cells. Activation of multiple effector cell
types might be the key to curative cancer vaccination. In
this regard, interleukin 12-p70 is an important factor that
stimulates efficient immunity. Attention should be paid to the
generation procedure of the cellular vaccine so that the DC
will still be able to produce interleukin 12 following injection.
The outcome of DC vaccination might probably be further
enhanced by making it part of a combination therapy that
combines immune activationwith attacking the immunosup-
pressive tumor microenvironment.
In summary, this special issue illustrates the function
of various DC subsets and their contribution to tissue
homeostasis. A better comprehension of the DC subsets and
the networks they operate on may provide novel biomarkers
to diagnose, prognosticate, and monitor disease. In addition,
itmay provide insights into improving the effectiveness ofDC
based immunotherapy.
Jurjen Tel
Daniel Benitez-Ribas
Edith M. Janssen
Evelien L. J. Smits
Joannes F. M. Jacobs
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
